

An Overview on Tuberculosis (TB)

Prakash Teron¹, Rahul Singh Kushwaha¹, Atul Tiwari², Kaushal K. Chandrul³

¹Pharmacy Graduate, ²Associate Professor & Researcher, ³Faculty of Research and Development

^{1,2,3}Mewar University, Chittorgarh, Rajasthan, India

How to cite this paper: Prakash Teron | Rahul Singh Kushwaha | Atul Tiwari | Kaushal K. Chandrul "An Overview on Tuberculosis (TB)" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-3 | Issue-3, April 2019, pp.1820-1825, URL: <https://www.ijtsrd.com/papers/ijtsrd23543.pdf>



IJTSRD23543

Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (<http://creativecommons.org/licenses/by/4.0>)



INTRODUCTION

Tuberculosis (TB) is one of the principal old-fashioned sicknesses of humankind and has co-developed with individuals for various a large numbers of quite a while or perhaps for a couple of million years [1]. One out of three individuals over the world addressing 2-3 billion individuals are known to be spoiled with Mycobacterium Tuberculosis (M. Tuberculosis) of which 5-15% are probably going to make dynamic TB ailment in the midst of their lifetime[2]. The most prepared realized nuclear demonstrate of TB was perceived in a fossil of an ended bison (Pleistocene wild ox), which was radiocarbon dated at 17,870±230 years [3]. Disregarding the way that as ahead of schedule as 1689, it was developed by Dr. Richard Morton that the aspiratory shape was connected with "tubercles," because of the variety of its symptoms, TB was not recognized as a solitary[4]


Around the world, in 2015, there were 10.4 million new instances of TB and 1.8 million passing's inferable from the malady [5]. Through escalated look into, progress in the arrangement of coordinated patient consideration and execution of supportable wellbeing approaches, the World Health Organization (WHO) has set an objective of diminishing the TB frequency rate by 90% and the quantity of TB-related passing's by 95% continuously 2035, as illustrated in its 'End TB Strategy' [6]. A definitive point is to accomplish worldwide destruction of TB. In any case, to accomplish these aspirations, a few difficulties

ABSTRACT

Tuberculosis (TB) stays one of the deadliest irresistible ailments in charge of millions of passing's every year over the world. In this paper we present a general review of TB including the pathogenesis, analysis, and treatment rules. In readiness of this review, we scanned PubMed for pertinent articles on TB. Furthermore, we looked through the sites of global establishments like the World Health Organization (WHO) and the US Centers for Disease control and Prevention (CDC) for related reports and clinical rules. This paper has been composed with the goal to offer general training to wellbeing experts, arrangement producers, patients and the general population.

KEYWORDS: Tuberculosis(TB); Global epidemiology; Pathogenesis of TB; Risk factor drug resistant TB; Diagnosis; Prevention; Treatment of TB

relating to TB the executives should be survived. Notwithstanding tending to the weight of malady brought about by medication touchy TB, it is critical to handle the expanding risk of multidrug-safe (MDR) TB, characterized as TB brought about by M. tuberculosis disconnects that are impervious to both rifampicin and isoniazid [5]. Since the safe structure in sound people dividers off the causative infinitesimal life forms, TB malady in strong people is as often as possible asymptomatic. This bacterium lives and copies in the macrophages, accordingly avoiding the typical opposition system in the patient's serum. Sullyng with TB can result in two stages: Latent Tuberculosis Infection(LTBI) or tuberculosis disorder. Accepting left untreated, the death rate with this malady is over half. For this survey article, information accessible at the official sites of World Health Organization(WHO); from the Ministry of Health, Government of India; through PubMed focal and Google scholar web crawlers were broadly counseled This article gives a report on the clinical way to deal with overseeing drug-touchy, sedate safe and inert TB. The worldwide the study of disease transmission of the sickness, clinical introduction and ways to deal with the board are talked about. Future research and clinical needs are considered. We should keep on directing examination to streamline conveyance of viable intercessions, just as grow new instruments that can expand intruding on tuberculosis transmission



Anticipated quickening in the decay of worldwide tuberculosis frequency rates to target levels. From WHO END TB Strategy[7].

The resistant framework in sound individuals dividers off the causative microscopic organisms, TB disease in solid individuals is regularly asymptomatic. This bacterium lives and increases in the macrophages, consequently dodging the regular protection framework in the patient's serum. Contamination with TB can result in two phases: asymptomatic idle tuberculosis contamination (LTBI) or tuberculosis malady. Whenever left untreated, the death rate with this ailment is over half. For this survey article, information accessible at the official sites of World Health Organisation (WHO); from the Ministry of Health, Government of India; through PubMed focal and Google scholar® web search tools were broadly counseled.

GLOBAL EPIDEMIOLOGY

Careful appraisals of TB rate rely upon generous national perception segments that hope to address issues of under-reporting. TB rate per country may be surveyed using distinctive systems: case see data may be united with ace assessments on the conceivable dimension of under-specifying and under-discovering; high-compensation countries may apply a change factor to their declared notice number to speak to under-uncovering and under-investigation; recurrence may be assessed using results from TB inescapability ponders [1].

There was a 1.5% decrease in TB rate all around some place in the scope of 2014 and 2015. In 2015, the country with the most amazing load of TB illness was India, with a normal hard and fast TB recurrence of 2.84 million (powerlessness between time 1.47- 4.65 million). Of the 10.4 million scene TB cases that year, 60% of cases were represented from the going with six countries in lessening solicitation of event: India, Indonesia, China, Nigeria, Pakistan and South Africa. By region, 61% of cases were in Asia; 26% in Africa; 7% in the Eastern Mediterranean; 3% in Europe; and 3% in the Americas. HIV coinfection was represented in 11% of cases and was most conspicuous in countries in southern Africa [1].

Around a similar time, there were 1.4 million passings from TB among HIV-opposite people (19 for each 100,000 masses), of which 84% occurred in Africa and Southeast Asia. There were a further 0.39 million passings from TB among HIV-constructive individuals. India and Nigeria spoke to 43% of the full scale number of TB passings among HIV-critical and HIV-useful people joined. All

landmasses and there has been a 34% reduction in the TB demise rate some place in the scope of 2000 and 2015 [1].

MDR TB and rifampicin-safe (RR) TB spoke to 3.9% of new TB cases and 21% of as of late treated TB cases in 2015. MDR and RR TB spoke to 580,000 occurrences of scene TB cases and 250,000 passings all around. China, India and Russia spoke to 45% of the overall outright MDR and RR TB case inconvenience [1]

PATHOGENESIS OF TB

TB is an airborne bacterial infection caused by *M. Tuberculosis* which affects any part of the body and most commonly the lungs[8]. Tuberculosis is transmitted by inhalation of aerosolised droplets (1–5µm in diameter) from an infected person coughing, sneezing or talking. Droplets are deposited in the alveoli, where the bacteria are ingested by alveolar macrophages, resulting in a series of host-pathogen interactions. Thirty per cent of exposed individuals become infected. In 90 per cent of infected people, the infection is contained by host responses and becomes latent. The remaining 10 per cent develop progressive primary tuberculosis.

Mycobacteria are intracellular pathogens that can survive and multiply within macrophages. During primary infection, infected macrophages are carried by the lymphatic system to regional lymph nodes, but may disseminate throughout the body via the bloodstream. This may result in seeding to extra-pulmonary sites, where the infection can lie dormant until it is reactivated, or disseminated active infection. Five per cent of individuals with latent TB will develop active disease within two years, and another five per cent will develop it at some point in their lives[9]. The small unaffected proportion multiplies within the macrophages and is released upon death of the macrophages. Live released tubercle bacilli spread via the bloodstream or lymphatic channels to any part of the body tissues or organs in addition to highly susceptible areas of TB infection such as the lungs, larynx, lymph nodes, spine, bone or kidneys [10]. In about 2 to 8 weeks[11]. An immune response is triggered which allows white blood cells to encapsulate or destroy majority of the tubercle bacilli. The encapsulation by the white blood cells results in a barrier around the tubercle bacilli forming a granuloma [12]. On the other hand, if the immune system fails to keep the tubercle bacilli under control, rapid multiplication of the bacilli ensues which leads to a progression from LTBI to a case of TB. The time for progression to TB may be soon after LTBI or longer occurring after many years. A TB case is highly infectious

DIAGNOSIS

Analysis of TB needs to assess clinical history, microbiological results and radiological discoveries.

Clinical history and risk factors for TB

Clinical indications of TB sickness rely on the site of TB contamination. Traditionally, aspiratory TB is described by a past filled with constant hack, sputum generation, haemoptysis, fever, night sweats and weight loss[14]. On account of additional pneumonic TB (i.e., TB creating outside the lungs), showing side effects will frequently be managed by the piece of the body influenced, albeit, a few indications, for example, loss of craving, night sweat and fever might be more general[15].

- For TB meningitis for example, patients may give cerebral pain or confusion [16] Central sensory system TB may show as TB meningitis, tuberculomas or TB mind abscesses [17].
- TB lymphadenitis is described by effortless, dynamic lymph hub swelling [18]. Cervical chain lymph hubs are the commonest site [19].
- Whereas patients encountering TB of the spine may give extreme back agony [20,21].
- TB peritonitis is portrayed most normally by stomach torment, fever and weight reduction. Other gastrointestinal indications incorporate loose bowels, ascites, hepatomegaly and splenomegaly [22];
- Genitourinary TB may result in dysuria, haematuria, flank torment, pelvic provocative ailment and epididymal masses relying upon the particular site of contamination [23];
- TB pericarditis is uncommon, described by side effects of chest torment, hack and dyspnoea and clinical discoveries incorporate fever, tachycardia, cardiomegaly and a pericardial rub [24].

This is then trailed by physical examination which assesses the person's complete condition and illuminates symptomatic techniques. In any case, the physical examination isn't expected to affirm or discount TB.

Testing for M. Tuberculosis is accomplished either through skin or blood tests. The skin test is known as Mantoux tuberculin test which is started by infusing a standard portion of tuberculin liquid into the skin of the lower part of the arm [25]

RISK FACTOR FOR DRUG RESISTANT TB

From a microbiological perspective, MDR-TB and XDR-TB are brought about by hereditary transformation of the M. Tuberculosis which renders hostile to TB specialists incapable against the freak tubercle bacilli [26]. Be that as it may, Caminero [27] proposes two classes of hazard factors for medication safe tuberculosis. The primary classification, he depicts as 'those encouraging the choice of obstruction in the network' and the second as 'explicit conditions that seem to build some patient's defencelessness to opposition' [27].

Factors facilitating the selection of resistance in the community

The major contributing component to the advancement of medication safe TB in networks is poor National Tuberculosis Programs (NTP). This might be because of absence of subsidizing to encourage preparing of staff and execution of regulatory controls towards patient

administration. Another contributing element might be absence of DOTS (Directly Observed Therapy Short Course) system usage or its productivity where they are actualized which may result in insufficient or absence of treatment monitoring[27].

Insufficiency in medication supply Characterized by incessant medication deficiencies, unacceptable Quality of accessible medications or improper routine or Dosage can likewise add to expanding danger of safe Tuberculosis. In an overview on isoniazid supply led By the United States' National Tuberculosis Controllers Association (NTCA) in January, 2013, ends on Patient consideration obstructions were made about 79% of wellbeing Facilities announced acquirement troubles of isoniazid Within the period of December, 2012 alone[28]. Then again, 15% revealed stopped supply of isoniazid within that month. This thus prompted 69% of thehealth offices exchanging providers of isoniazid whiles 68% deferred treatment of LTBI and 88% changing to Alternative routine. Such irregularities increment odds of medication safe TB just as transmission. Patients can Also add to expanding the danger of medication safe Tuberculosis. This is made conceivable when patients getting Treatment don't hold fast to treatment routine because of Lack of cash to bear the cost of treatment, social derision or Treatment inconvenience by occurrence of unfavorable occasions [29].

Specific conditions which increase some patients' Vulnerability to resistance

Caminero [27] further classifies the dangers of procuring Drug-safe TB into three arrangements of defenseless gatherings. The First gathering are patients who dependent on bacteriological outcomes Are delegated being at high danger of medication safe TB. These patients have a place with the Category II TB treatment Failures including 2 months of isoniazid, rifampicin, Pyrazinamide, Ethambutol and streptomycin, trailed By multi month of isoniazid, rifampicin, pyrazinamide and Ethambutol and a 5-month consistent period of isoniazid, Rifampicin and Ethambutol. Other high hazard patients for Drug-safe TB are those grouped under Category I and II who have flopped on two events, rifampicin Containing routine [29,30] and furthermore territories which don't Have access to DST labs. The second gathering of Patients is the individuals who are at high danger of medication safe TB Based on close contact with medication safe TB patients or patients named Category I TB routine disappointment. Close contacts with MDR-TB cases have been accounted for to have an alternate safe strain from the file case [29, 31]. Because of this high danger of obtaining MDR-TB, suspected Close contacts with MDR-TB cases are started comparative TB Regimen to the file case without DST results and subsequently altered when DST results are accessible. For patients with Category I treatment disappointment, the danger Of MDR-TB is variable from among nations. Under this Condition, a few nations record low MDR-TB rate, for example, Malawi [32] and Benin [33]. Certain drugs, for example, corticosteroids and infliximab (an enemy of α TNF monoclonal counter acting agent), are winding up progressively vital hazard factors, particularly in the created world.[34] Hereditary helplessness additionally exists,[35] for which the general significance remains undefined.[34]



Tuberculosis prevention poster from the United States, c. 1940

One of the real endeavours of WHO and its accomplices is to Ensure preventive measures toward stopping the expanding Prevalence of medication safe TB [35]. Inside various Countries, there is the requirement for essential research to Determine factors adding to treatment default Within various nations, there is the requirement for essential research to decide factors adding to treatment default [35]. The World Health Organization has made some progress with improved treatment regimens, and a little abatement in the event that numbers.[34] The US Preventive Services Task Force (USPSTF) suggests screening individuals who are at high hazard for idle tuberculosis with either tuberculin skin tests or interferon-gamma discharge assays[36].

Another method for forestalling drug safe TB is to improve adherence of patients to treatment. This can be accomplished by creating understanding consideration plans went for isolated treatment alternatives (i.e., inpatient, outpatient or network based treatment) just as diminishing pill trouble in TB routine methodology. A grouped randomized controlled preliminary led by Thiam et al. [37] in Senegal to survey new imperative proposition on improving patient adherence to TB treatment realized 88% treatment accomplishment in the intervention bundle differentiated and 76% in the control gathering. In addition, tolerant default rate was diminished to 5.5% in the intervention group instead of 16.8% in the control gathering. A bit of the interventions investigated were apportioning greater chance to controlling what's more, correspondence between human administrations providers and TB patients, decentralizing treatment outlets to stations nearer to patients, choice of DOT supporter by patient and fortifying supervision works out.

Vaccines

The only available vaccine as of 2011 is Bacillus CalmetteGuerin (BCG).[38] In children it decreases the risk of getting the infection by 20% and the risk of infection turning into active disease by nearly 60%.[39]

It is the most generally utilized immunization around the world, with over 90% of all youngsters being vaccinated.[40] The resistance it instigates diminishes after around ten years.[40] As tuberculosis is remarkable in the majority of Canada, the United Kingdom, and the United States, BCG is regulated to just those individuals at high risk.[41,42,43] Part of the thinking against the utilization of the antibody is that it makes the tuberculin skin test dishonestly positive, decreasing the test's helpfulness as a screening tool.[43] various new

Checking treatment routine is cantered around following Record of treatment reaction and taking suitable Actions, overseeing interference of treatment, companion Evaluation of treatment results and the recognition and Management of medication incited unfriendly responses [44]. Record Of treatment reaction is accomplished by performing sputum Smear microscopy and culture at customary interims and the Regimen acclimated to suit the proper weakness Pattern [45]. Furthermore, month to month estimation of Patient's weight is prescribed to educate weight Depended portion changes [46]. Treatment intrusions by defaulting patients or HIV co-contamination are recorded and patients returning after default are tried again for Drug defenselessness [44]. Accomplice assessment of treatment Outcomes helps in getting to the treatment achievement of a specific decision of routine just as the adequacy of the medications included. Antagonistic responses are intently checked By wellbeing work force through perceptions and record of Signs and indications [47]. Patients are additionally informed on likely Symptoms of medication instigated unfriendly impacts to energize Reporting of their occurrence. Fix is accomplished for TB Treatment because of an aggregate exertion of the patient And TB program staff. All things considered, tolerant supervision and backing through Directly Observed Treatment Short course (DOTS). Under DOTS, the TB program staffs watch the admission of each portion on the treatment routine guaranteeing the patient takes the correct medication with the right dosages and at the fitting interims [48]. Specks additionally upgrade correspondence among patient and staff which opens open doors for further TB instruction, early distinguishing proof of non-adherence and unfavourable responses [44, 48, 49].

CONCLUSION

Tuberculosis stays a standout amongst the most fatal irresistible Diseases and has guaranteed a huge number of lives for a long time. While noteworthy advancement has been made towards controlling the worldwide weight of TB over the previous decade, more endeavours are as yet required. Developing issues, for example, multi Drug-obstruction takes steps to return the advancement made Regarding TB care and control. The information base for TB remains a quickly extending zone and worldwide rules are ceaselessly being refined for example to consolidate new Anti-tubercular medications to handle issues of obstruction. Wellbeing Professionals, strategy producers, patients and the overall population need to stay up with the latest with current patterns in TB Management and control. This will be basic for productive Adoption of worldwide rules to nation level circumstance, especially thinking about issues, for example, ailment Burden, wellbeing framework structures and accessible assets.

REFERENCE

- [1] Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW, Small PM. Stable association between strains of *Mycobacterium tuberculosis* and their human host populations. Proc Natl Acad Sci USA. 2004;101:4871-6.[PMC free article] [PubMed] [Google Scholar]
- [2] World Health Organisation. 2015 Global Tuberculosis Report. Geneva, Switzerland: WHO, 2015.

- [3] Rothschild BM, Martin LD, Lev G, Bercovier H, Bar-Gal GK, Greenblatt CL, et al. *Mycobacterium tuberculosis* Complex DNA from an Extinct Bison Dated 17,000 Years before the Present. *Clin Infect Dis*. 2001; 33:305-11. [PubMed] [Google Scholar]
- [4] News-medical.net [Internet]. History of Tuberculosis. [Last cited on 2010 Oct 15]. Available from: <http://www.news-medical.net/health/History-of-Tuberculosis.aspx>.
- [5] World Health Organisation. WHO Global Tuberculosis Report 2016. WHO, 2016. Accessed on 1st July 2017. Available online: http://www.who.int/tb/publications/global_report/en/
- [6] World Health Organisation. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. WHO, 2016. Accessed on 1st July 2017. Available online: http://www.who.int/tb/post2015_TBstrategy.pdf?ua=1
- [7] Barnagarwala T. TB hospital staff live under shadow of dreaded disease. *The Indian Express*. Uttar Pradesh, India: IE Online Media Services, 2014
- [8] Dye C, Floyd K. Tuberculosis. In: Jamison DT, Breman JG, Measham AR, et al. editors. *Disease Control Priorities in Developing Countries*, 2nd Ed. New York: Oxford University Press, 2006.
- [9] Collins HL, Kaufmann SHE. Prospects for better tuberculosis vaccines. *Lancet Infectious Diseases* 2001; 1:21-8.
- [10] Smith I. *Mycobacterium tuberculosis* pathogenesis and molecular determinants of virulence. *Clin Microbiol Rev*. 2003; 16:463-96.
- [11] Haley CA. Prevention of Tuberculosis: TB Screening, Diagnosis of Latent Tuberculosis Infection and Preventive Therapy. South-eastern National Tuberculosis Centre, 2013 [August 12 2016]. Available online: <https://sntc.medicine.ufl.edu/Files/Haiti/Module%2005%20Diagnosis%20and%20Treatment%20of%20LTBI%20ENGLISH.pdf>
- [12] Schluger NW. The pathogenesis of tuberculosis: the first one hundred (and twenty-three) years. *Am J Respir Cell Mol Biol* 2005; 32:251-6.
- [13] CDC. Chapter 2: Transmission and Pathogenesis of Tuberculosis [August 15 2016]. Available online: <https://www.cdc.gov/tb/education/corecurr/pdf/chapter2.pdf>
- [14] Lawn SD, Zumla AI. Tuberculosis. *Lancet* 2011; 378:57-72. [Crossref] [PubMed]
- [15] Lee JY. Diagnosis and treatment of extra pulmonary tuberculosis. *Tuberc Respir Dis (Seoul)* 2015; 78:47-55.
- [16] CDC. Chapter 4: Diagnosis of Tuberculosis Disease [August 15 2016]. Available online: <https://www.cdc.gov/tb/education/corecurr/pdf/chapter4.pdf>
- [17] Rock RB, Olin M, Baker CA, et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. *Clin Microbiol Rev* 2008; 21:243-61. [Crossref] [PubMed]
- [18] Artenstein AW, Kim JH, Williams WJ, et al. Isolated peripheral tuberculous lymphadenitis in adults: current clinical and diagnostic issues. *Clin Infect Dis* 1995; 20:876-82. [Crossref] [PubMed]
- [19] Polesky A, Grove W, Bhatia G. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. *Medicine (Baltimore)* 2005; 84:350-62. [Crossref] [PubMed]
- [20] Cormican L, Hammal R, Messenger J, et al. Current difficulties in the diagnosis and management of spinal tuberculosis. *Postgrad Med J* 2006; 82:46-51.
- [21] Rasouli MR, Mirkoohi M, Vaccaro AR, et al. Spinal tuberculosis: diagnosis and management. *Asian Spine J* 2012; 6:294-308.
- [22] Sanai FM, Bzeizi KI. Systematic review: tuberculous peritonitis--presenting features, diagnostic strategies and treatment. *Aliment Pharmacology Ther* 2005; 22:685-700. [Crossref] [PubMed]
- [23] Kapoor R, Ansari MS, Mandhani A, et al. Clinical presentation and diagnostic approach in cases of genitourinary tuberculosis. *Indian J Urol* 2008; 24:401-5. [Crossref] [PubMed]
- [24] Trautner BW, Darouiche RO. Tuberculous pericarditis: optimal diagnosis and management. *Clin Infect Dis* 2001; 33:954-61. [Crossref] [PubMed]
- [25] CDC. Testing for TB infection 2016 [August 12 2016]. Available online: <http://www.cdc.gov/tb/topic/testing/tbtesttypes.htm>
- [26] Migliori GB, Centis R, Lange C, et al. Emerging epidemic Of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global Perspectives. *Curr Opin Pulm Med* 2010; 16:171-9.
- [27] Caminero JA. Multidrug-resistant tuberculosis: Epidemiology, risk factors and case finding. *Int J Tuberc Lung Dis* 2010; 14:382-90.
- [28] World Health Organization. Guidelines for the Programmatic management of drug resistant tuberculosis 2011 Update. Geneva, Switzerland: WHO, 2011.
- [29] Centers for Disease Control and Prevention (CDC). Impact of a shortage of first-line anti tuberculosis Medication on tuberculosis control - United States, 2012-2013. *MMWR Morb Mortal Wkly Rep* 2013; 62:398-400.
- [30] Suarez PG, Floyd K, Portocarrero J, et al. Feasibility And cost-effectiveness of standardised second-line drug Treatment for chronic tuberculosis patients: a national Cohort study in Peru. *Lancet* 2002; 359:1980-9.
- [31] Kritski AL, Marques MJ, Rabahi MF, et al. Transmission Of tuberculosis to close contacts of patients with Multidrug-resistant tuberculosis. *Am J Respir Crit Care Med* 1996; 153:331-5.

- [32] Harries AD, Nyirenda TE, Kemp JR, et al. Management and outcome of tuberculosis patients who fail treatment under routine programme conditions in Malawi. *Int J Tuberc Lung Dis* 2003; 7:1040-4.
- [33] Trébuq A, Anagonou S, Gninafon M, et al. Prevalence Of primary and acquired resistance of Mycobacterium Tuberculosis to anti tuberculosis drugs in Benin after 12 Years of short-course chemotherapy. *Int J Tuberc Lung Dis* 2010;14
- [34] Lawn SD, Zumla AI (July 2011). "Tuberculosis". *Lancet*. 378 (9785): 57-72. Doi:10.1016/S0140-6736(10)62173-3. PMID 21420161
- [35] Möller M, Hoal EG (March 2010). "Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis". *Tuberculosis*. 90 (2): 71-83. Doi:10.1016/j.tube.2010.02.002. PMID
- [36] Bibbins-Domingo K, Grossman DC, Curry SJ, Bauman L, Davidson KW, Epling JW, García FA, Herzstein J, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Pignone MP (September 2016). "Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement". *JAMA*. 316 (9): 96269. Doi:10.1001/jama.2016.11046. PMID
- [37] Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. *JAMA* 2007; 297:380-6.
- [38] McShane H (October 2011). "Tuberculosis vaccines: beyond bacilli Calmette-Guerin". *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences*. 366 (1579): 2782-89. Doi:10.1098/rstb.2011.0097. PMC 3146779. PMID 21893541
- [39] Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, Abubakar I (August 2014). "Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis". *BMJ*. 349: g4643. Doi:10.1136/bmj.g4643. PMC 4122754. PMID
- [40] World Health Organization. "Global tuberculosis control—surveillance, planning, financing WHO Report 2006". Archived from the original on 12 December 2006. Retrieved 13 October 2006.
- [41] Chaisson RE, Martinson NA (March 2008). "Tuberculosis in Africa – combating an HIV-driven crisis". *The New England Journal of Medicine*. 358 (11): 1089-92. Doi:10.1056/NEJMp0800809. PMID 18337598.
- [42] Griffith DE, Kerr CM (August 1996). "Tuberculosis: disease of the past, disease of the present". *Journal of Perianesthesia Nursing*. 11 (4):240-45. Doi:10.1016/S1089-9472(96)80023-2. PMID 8964016.
- [43] "Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society". *MMWR. Recommendations and Reports*. 49 (RR-6): 1-51. June 2000. PMID 10881762. Archived from the original on 17 December 2004.
- [44] World Health Organization. Treatment of Tuberculosis, Fourth Edition. Geneva, Switzerland: WHO, 2010. World Health Organization. WHO Treatment guidelines for drug-resistant tuberculosis; 2016 Update. Geneva, Switzerland: WHO, 2016.
- [45] TB CARE I. International Standards for Tuberculosis Care, Edition 3. The Hague: TB CARE I, 2014.
- [46] Warmelink I, ten Hacken NH, van der Werf TS, et al. Weight loss during tuberculosis treatment is an important Risk factor for drug-induced hepatotoxicity. *Br J Nutr* 2011; 105:400-8.
- [47] Lorent N, Sebatunzi O, Mukeshimana G, et al. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. *PLoS One* 2011; 6:e19566.
- [48] Davies PD. The role of DOTS in tuberculosis treatment and control. *Am J Respir Med* 2003; 2:203-9?
- [49] Sandhu GK. Tuberculosis: current situation, challenges and overview of its control programs in India. *J Glob Infect Dis* 2011; 3:143-50.